• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjects

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Moderate to high dose cyclophosphamide and intercalated Corynebacterium parvum in patients with metastatic lung cancer.

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Thatcher, Nick
    Honeybourne, D
    Wagstaff, John
    Carroll, K B
    Barber, Philip V
    Morrison, J B
    Crowther, Derek
    Affiliation
    The Manchester Lung Tumour Group; Cancer Research Campaign Department of Medical Oncology, Christie Hospital and Holt Radium Institute, Manchester, UK.
    Issue Date
    1984-01
    
    Metadata
    Show full item record
    Abstract
    Thirty-nine patients with histologically proven widely metastatic bronchogenic carcinoma were treated with cyclophosphamide and Corynebacterium parvum. The dosage of cyclophosphamide was higher than conventional as previous work had indicated better results with increased dosage. Experimental work had suggested that the addition of Corynebacterium parvum would increase the antitumour effect and possibly reduce the cyclophosphamide induced granulocytopenia. A short treatment programme using three i.v. injections of cyclophosphamide, 1.5 g/m2, 2.5 g/m2 then 3.5 g/m2, at 3 week intervals were given. Four days after each cyclophosphamide injection, C. parvum 2 mg/m2 i.v. was administered. An overall 38% tumour response rate was observed, 18% for patients with non-small-cell carcinoma and 65% for small-cell carcinoma patients. The median survival for the 39 patients was 5 months (range 1-16+ months). These results, particularly for the non-small-cell patient group are comparable to those obtained with intensive combination chemotherapy regimens administered intermittently over much longer periods. An important consideration, objectively assessed in the present study, was the effect of treatment on quality of life and breathlessness. Improvement was noted not only in those patients with tumour response but also in a proportion of those who did not fulfil the criteria of response. Toxicity was also carefully assessed and, although the cyclophosphamide dosages were higher than conventionally used, no undue problems were noted. The addition of C. parvum did not have any noticeable beneficial effect. Cyclophosphamide given at dosages higher than is usual but which do not require bone marrow rescue is worthy of further study.
    Citation
    Moderate to high dose cyclophosphamide and intercalated Corynebacterium parvum in patients with metastatic lung cancer. 1984, 78 (1):89-97 Br J Dis Chest
    Journal
    British Journal of Diseases of the Chest
    URI
    http://hdl.handle.net/10541/108058
    DOI
    10.1016/0007-0971(84)90101-3
    PubMed ID
    6318791
    Type
    Article
    Language
    en
    ISSN
    0007-0971
    ae974a485f413a2113503eed53cd6c53
    10.1016/0007-0971(84)90101-3
    Scopus Count
    Collections
    All Christie Publications

    entitlement

    Related articles

    • Immunochemotherapy in 34 cases of oat cell carcinoma of the lung with 19 complete responses.
    • Authors: Israël L, Depierre A, Choffel C, Milleron B, Edelstein R
    • Issue date: 1977 May-Jun
    • Chemotherapy versus chemoimmunotherapy with levamisole or Corynebacterium parvum in advanced lung cancer.
    • Authors: Chahinian AP, Goldberg J, Holland JF, Reisman A, Jaffrey IS, Mandel EM
    • Issue date: 1982 Jun
    • Chemo-immunotherapy for unresectable bronchogenic carcinoma.
    • Authors: Sarna GP, Lowitz BB, Haskell CM, Dorey FJ, Cline MJ
    • Issue date: 1978 May
    • Combination chemotherapy plus methanol extracted residue of bacillus Calmette-Guérin or Corynebacterium parvum in stage III lung cancer.
    • Authors: Bjornsson S, Takita H, Kuberka N, Preisler H, Catane H, Higby D, Henderson E
    • Issue date: 1978 Apr
    • Doxorubicin, cisplatin, and Corynebacterium parvum in non-small cell bronchogenic carcinoma.
    • Authors: Drapkin R, Bjornsson S, Naeher C, Higby D, Caracandas J, Wallens WT, Kuberka N, Suh K, Siddiqi N, Henderson ES
    • Issue date: 1980
    DSpace software (copyright © 2002 - 2023)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.